About: Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
Creator	Kim, Jae-Ouk Rho, Semi Song, Manki Park, Uni Cho, Nam Choi, Jung-Ah Goo, Junghyun Jeong, Yuji Jung, Dae-Im Lee, Hyeja Lee, Jae Park, Pil-Gu Park, Young-Shin Seo, Sang Sung, Hyeyeong Yang, Eunji
Source	Elsevier; Medline; PMC
abstract	Abstract Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe pulmonary infection, with ∼35 % mortality. Spike glycoprotein (S) of MERS-CoV is a key target for vaccines and therapeutics because S mediates viral entry and membrane-fusion to host cells. Here, four different S subunit proteins, receptor-binding domain (RBD; 358–606 aa), S1 (1–751 aa), S2 (752–1296 aa), and SΔTM (1–1296 aa), were generated using the baculoviral system and immunized in mice to develop neutralizing antibodies. We developed 77 hybridomas and selected five neutralizing mAbs by immunization with SΔTM against MERS-CoV EMC/2012 strain S-pseudotyped lentivirus. However, all five monoclonal antibodies (mAb) did not neutralize the pseudotyped V534A mutation. Additionally, one mAb RBD-14F8 did not show neutralizing activity against pseudoviruses with amino acid substitution of L506 F or D509 G (England1 strain, EMC/2012 L506 F, and EMC/2012 D509 G), and RBD-43E4 mAb could not neutralize the pseudotyped I529 T mutation, while three other neutralizing mAbs showed broad neutralizing activity. This implies that the mutation in residue 506–509, 529, and 534 of S is critical to generate neutralization escape variants of MERS-CoV. Interestingly, all five neutralizing mAbs have binding affinity to RBD, although most mAbs generated by RBD did not have neutralizing activity. Additionally, chimeric antibodies of RBD-14F8 and RBD-43E4 with human Fc and light chain showed neutralizing effect against wild type MERS-CoV KOR/KNIH/002, similar to the original mouse mAbs. Thus, our mAbs can be utilized for the identification of specific mutations of MERS-CoV.
has issue date	2020-03-31(xsd:dateTime)
bibo:doi	10.1016/j.virusres.2020.197863
bibo:pmid	31945421
has license	els-covid
sha1sum (hex)	fe6d815c8419976b55dc3f1548eccb0a47f68b81
schema:url	https://doi.org/10.1016/j.virusres.2020.197863
resource representing a document's title	Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
has PubMed Central identifier	PMC7114870
has PubMed identifier	31945421
schema:publication	Virus Research
resource representing a document's body	covid:fe6d815c8419976b55dc3f1548eccb0a47f68b81#body_text
is schema:about of	named entity 'VACCINES' named entity 'SUBUNIT' named entity 'IMMUNIZED' named entity 'IDENTIFICATION' named entity 'CAUSES' named entity 'BROAD' named entity 'VARIANTS' named entity 'MEMBRANE' named entity 'IMMUNIZATION' named entity 'PULMONARY INFECTION' named entity 'USING' named entity 'LENTIVIRUS' named entity 'AMINO ACID SUBSTITUTION' named entity 'DID' named entity '28S' named entity '1296' named entity 'HERE' named entity 'LIGHT CHAIN' named entity 'HOST CELLS' named entity 'FUSION' named entity 'ACTIVITY' named entity 'HUMAN' named entity 'THERAPEUTICS' named entity 'generated' named entity 'neutralizing' named entity 'MERS-CoV' named entity 'mAb' named entity 'binding affinity' named entity 'developed' named entity 'glycoprotein' named entity 'key' named entity 'mutation' named entity 'neutralizing antibodies' named entity 'MUTATION' named entity 'HAVE' named entity 'CORONAVIRUS' named entity 'NOVEL' named entity '509' named entity 'ESCAPE' named entity 'TARGET' named entity 'SELECTED' named entity 'STRAIN' named entity 'MERS' named entity 'CHARACTERIZATION' named entity 'SPIKE PROTEIN' named entity 'MICE' named entity 'DOMAIN' named entity 'PROTEINS' named entity '529' named entity 'IS A' named entity 'SYSTEM' named entity 'RBD' named entity 'OUR' named entity 'MOUSE' named entity 'CHIMERIC' named entity 'SIMILAR' named entity 'BACULOVIRAL' named entity 'KOR' named entity 'KEY' named entity 'EMC' named entity 'SPECIFIC' named entity 'RECEPTOR' named entity 'MONOCLONAL ANTIBODIES' named entity 'CRITICAL' named entity '534' named entity 'EFFECT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software